Axxion S.A.’s Gilead Sciences GILD Stock Holding History

Axxion S.A.’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.55M	Buy	+12,294	New	+$1.62M	0.11%	129

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Axxion S.A.'s GILD Position: Q2 2026 in Review

Axxion S.A. opened a new position in Gilead Sciences (GILD) in Q2 2026: 12,294 shares worth $1.55M. The stake represents 0.11% of the portfolio and ranks #129 among its holdings.

2,116 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Axxion S.A. held 12,294 shares of Gilead Sciences worth $1.55M as of Q2 2026.
Gilead Sciences was a new Axxion S.A. position in Q2 2026.
Gilead Sciences made up 0.11% of Axxion S.A.'s portfolio in Q2 2026, its #129 holding.
2,116 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Axxion S.A.'s 13F filing for Q2 2026, filed 14 Aug 2026.